Pivotal Results Show Revumenib Holds Promise for Patients With KMT2Ar Acute Leukemia

In AUGMENT-101, patients with R/R KMT2Ar acute leukemia had high overall response rates; despite being heavily pretreated, 40% were able to proceed to transplant and the KMT2Ar cohort was stopped early.

Related Keywords

California ,United States ,San Diego ,American ,Ibrahimt Aldoss , ,American Society Of Hematology Annual Meeting ,City Of Hope National Medical Center ,Hope National Medical Center ,American Society ,Hematology Annual Meeting ,American Journal ,Managed Care ,New Drug Application ,